Which is more appropriate for the evaluation of HCC, RECIST or mRECIST criteria?

Dig Liver Dis. 2024 Feb;56(2):381. doi: 10.1016/j.dld.2023.11.029. Epub 2023 Dec 8.

Authors

Yong Xie¹, Tianshi Lyu¹, Jian Wang², Yinghua Zou¹

Affiliations

¹ Department of Interventional Radiology and Vascular Surgery, Peking University First Hospital, Beijing, China.
² Department of Interventional Radiology and Vascular Surgery, Peking University First Hospital, Beijing, China. Electronic address: jianwang0987@sina.com.

PMID: 38071182
DOI: 10.1016/j.dld.2023.11.029

No abstract available

Keywords: Hepatocellular carcinoma; Overall survival; RECIST; mRECIST.

Publication types

Letter

MeSH terms

Carcinoma, Hepatocellular* / diagnosis
Carcinoma, Hepatocellular* / therapy
Chemoembolization, Therapeutic*
Humans
Liver Neoplasms* / diagnosis
Liver Neoplasms* / therapy
Niacinamide
Response Evaluation Criteria in Solid Tumors
Retrospective Studies
Sorafenib
Treatment Outcome

Substances

Sorafenib
Niacinamide